GLP-1 Companion Products Market Exclusions The GLP-1 receptor agonist drugs, such as Ozempic, Wegovy, and Mounjaro, are not included in the market because they represent a different therapeutic market (pharmaceutical therapeutics)
The abrupt cessation of GLP-1R agonists in individuals with metabolic disorders may lead to adverse effects, as seen in a case where a patient developed IIH after discontinuing duraglutide [29]
Hence, both CNS GIPR and GLP-1R signalling are required for the full weight loss effect of a GIPR-Ab/GLP-1 peptideantibody conjugate
For information about what happens after stopping, including how long side effects persist, see our guide to how long semaglutide stays in your system
Monitoring liver function during treatment is crucial, given that the study did not deploy invasive liver surveillance such as biopsies